2/3
07:00 am
fhtx
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
Low
Report
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
1/13
04:05 pm
fhtx
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Medium
Report
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
1/9
10:20 pm
fhtx
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
High
Report
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
12/20
01:30 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at
Wall Stre
High
Report
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at
Wall Stre
12/19
05:58 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
12/18
07:11 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
High
Report
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
12/6
01:36 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was downgraded by analysts at
Wall St
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) was downgraded by analysts at
Wall St
12/3
07:01 pm
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was given a new $12.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Foghorn Therapeutics (NASDAQ:FHTX) was given a new $12.00 price target on by analysts at Stifel Nicolaus.
11/29
12:31 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at
Wall Stre
Medium
Report
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at
Wall Stre
11/25
07:00 am
fhtx
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Medium
Report
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
11/17
06:19 am
fhtx
4D Molecular Therapeutics taps Kristian Humer as CFO [Seeking Alpha]
Low
Report
4D Molecular Therapeutics taps Kristian Humer as CFO [Seeking Alpha]
11/17
06:13 am
fhtx
4DMT Appoints Kristian Humer as Chief Financial Officer [Yahoo! Finance]
Low
Report
4DMT Appoints Kristian Humer as Chief Financial Officer [Yahoo! Finance]
11/7
08:45 am
fhtx
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $12.00 price target on the stock.
Medium
Report
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $12.00 price target on the stock.